Lacerta Therapeutics is focused on CNS-targeted treatments and lysosomal storage diseases. It is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases.